Physician profile
Elana Rose Eisner
NPI 1881671980
$15,085.77
in general payments reported to CMS, 2019-2025
29 companies · $2,772 in 2025
The $2,772 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,376 · 2020: $1,194 · 2021: $884 · 2022: $2,983 · 2023: $2,233 · 2024: $2,645 · 2025: $2,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,551 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,550.63 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,242.43 | 2019-2025 | Evenity, Otezla, Uplizna |
| Horizon Therapeutics Plc | $1,772.01 | 2019-2023 | Krystexxa |
| Ucb, INC. | $1,561.98 | 2019-2025 | Cimzia, Bimzelx |
| Genentech USA, INC. | $1,431.74 | 2019-2025 | Actemra, Rituxan |
| Abbvie INC. | $1,184.49 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,101.36 | 2019-2025 | |
| Janssen Biotech, INC. | $990.14 | 2020-2025 | Tremfya, Simponi Aria, Stelara |
| Astrazeneca Pharmaceuticals LP | $503.87 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $442.94 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $387.05 | 2020-2025 | Orencia |
| Genentech, INC. | $279.65 | 2019 | |
| Lilly USA, LLC | $260.53 | 2019-2025 | Taltz |
| Sobi, INC | $260.39 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.95 | 2022-2024 | Ofev |
| Ani Pharmaceuticals, INC. | $214.36 | 2023-2025 | Purified Cortrophin Gel |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $202.48 | 2019-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $193.39 | 2021-2023 | Lupkynis |
| Pacira Therapeutics, INC. | $180.06 | 2019-2020 | |
| Pfizer INC. | $157.29 | 2020-2025 | |
| Genzyme Corporation | $151.39 | 2020-2025 | |
| Sandoz INC. | $83.27 | 2023-2025 | Hyrimoz, Jubbonti |
| Organon LLC | $80.18 | 2023-2024 | Renflexis, Hadlima |
| Alexion Pharmaceuticals, INC. | $36.98 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $34.86 | 2024 | Arcalyst |
| Tersera Therapeutics LLC | $33.86 | 2025 | Quzyttir |
| Pacira Pharmaceuticals Incorporated | $31.11 | 2023 | Iovera, Zilretta |
| Fresenius Kabi USA, LLC | $23.84 | 2025 | |
| Celltrion USA INC. | $18.28 | 2025 | Vegzelma |
| Janssen Scientific Affairs, LLC | $8.89 | 2023 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elana Eisner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.